search
Back to results

To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions

Primary Purpose

Depression

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions
Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
Sponsored by
Sandoz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression focused on measuring Antidepressant

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Active Comparator

    Arm Label

    1

    2

    3

    Arm Description

    Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.

    Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.

    Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.

    Outcomes

    Primary Outcome Measures

    Bioequivalence based on AUC and Cmax

    Secondary Outcome Measures

    Full Information

    First Posted
    June 2, 2009
    Last Updated
    March 27, 2017
    Sponsor
    Sandoz
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00913952
    Brief Title
    To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
    Official Title
    Comparative, Randomized, 3-way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fed and Fasted Conditions
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2009
    Overall Recruitment Status
    Completed
    Study Start Date
    April 1994 (undefined)
    Primary Completion Date
    June 1994 (Actual)
    Study Completion Date
    June 1994 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Sandoz

    4. Oversight

    5. Study Description

    Brief Summary
    To demonstrate the relative bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride capsules under fed and fasted conditions.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Depression
    Keywords
    Antidepressant

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    18 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Description
    Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
    Arm Title
    2
    Arm Type
    Experimental
    Arm Description
    Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
    Arm Title
    3
    Arm Type
    Active Comparator
    Arm Description
    Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
    Intervention Type
    Drug
    Intervention Name(s)
    Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions
    Intervention Type
    Drug
    Intervention Name(s)
    Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
    Intervention Type
    Drug
    Intervention Name(s)
    Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
    Primary Outcome Measure Information:
    Title
    Bioequivalence based on AUC and Cmax
    Time Frame
    53 days

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Richard Lalonde, Pharm.D.
    Organizational Affiliation
    Phoenix International Life Science Inc.
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions

    We'll reach out to this number within 24 hrs